Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD1 | P21728 | 3/20 | 0.38 |
| ▸ | DRD5 | P21918 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751230 | 1.00 | ADRA1A (0.40) | ADRA1AADRA1BADRA1DPLK1DRD2 | |
| SCHEMBL20553443 | 0.83 | OPRK1 (0.50) | — | |
| SCHEMBL21751215 | 0.82 | DRD4 (0.45) | DRD4SLC6A4 | |
| SCHEMBL20553462 | 0.74 | ADRB2 (0.56) | ADRA1AADRA1BADRA1DDRD2DRD1 | |
| SCHEMBL20551971 | 0.73 | ADRB2 (0.53) | HTR7 | |
| SCHEMBL21751224 | 0.72 | ADRA2A (0.52) | ADRA1AADRA1DDRD2DRD1DRD3 | |
| SCHEMBL20552201 | 0.72 | MCHR1 (0.38) | ADRA1ADRD2DRD1DRD5DRD3 | |
| SCHEMBL24410084 | 0.72 | OPRK1 (0.42) | — | |
| SCHEMBL20552725 | 0.72 | ADRA2A (0.42) | ADRA1ADRD2DRD1DRD3HTR1A | |
| SCHEMBL6844257 | 0.65 | HTR7 (0.50) | DRD2DRD1DRD5DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | DREXEL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | DREXEL UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409544-A1 | SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS | CX3CR1, CCR5, CCL2 | ADRA1A 480/4885ADRA1B 489/4885ADRA1D 387/4885 |
| US-12630555-B2 | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists | CX3CR1, CCL2, CCR2 | ADRA1A 233/4885ADRA1B 299/4885ADRA1D 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.